Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
CAMP4 Therapeutics Corp (CAMP)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$3.72-0.53%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for CAMP yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
EPS loss narrows toward -$0.79 in 2026 | A primary condition in CAMP4 Therapeutics Corp's published investment case. The stated target is EPS >= -0.79 USD per share. | Broken | EPS loss worsens beyond -0.79 in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative clinical-stage biotech, where the long-term thesis depends on research progress rather than established profits. The thesis is in a watch state: management is on track to start a Phase 1/2 trial, but recent performance trails its industry cohort and risk remains high.
The valuation model shows a 3.9 premium versus peers, while its low-confidence expectations-gap measure is negative and identifies optionality as the main source of valuation divergence. The evidence labels pricing as justified with low fragility, but does not establish that expectations are easy to meet.
Near term, CAMP remains loss-making, and a 44% estimated miss probability warrants attention at the next report. An August earnings beat is a positive data point, while cash was $86.4 million in the second quarter after a $50.1 million private placement; management says financing supports a runway into 2028, though cash declined from the prior quarter. For the multi-year view, trial initiation is anticipated in the second half of 2026, backed by regulatory clearance in Australia and Argentina and preclinical mouse-model data.
The key clinical swing factor is whether CAMP starts the CMP-002 Phase 1/2 trial on its stated timeline and advances the program with evidence that supports its potential. A guidance cut or further weakening in jobs data could add pressure, while strength among healthcare bellwethers may support the sector backdrop. Continued cash availability also matters as the company advances research.
Over the next 1 to 3 years, the long-term thesis is a high-risk bet on clinical progress and cash management, not on current earnings. Evidence is mixed: trial plans are on track, but profitability is absent and recent financial performance trails peers. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in CAMP4 Therapeutics Corp's published investment case. The stated target is >=44.9% YoY. |
| Intact |
| YoY revenue growth falls below 44.9% in FY26 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Successful collaboration with GSK and new board members | The company added a new board member. | Intact | Loss of key partnerships or leadership changes hurt growth | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.73 → $-0.80 · observed estimates
$0.01B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.73 | $5,842,857 | 5 / 5 |
| 2026-07-25 | $-0.73 | $5,842,857 | 5 / 5 |
| 2026-07-26 | $-0.73 | $5,842,857 | 5 / 5 |
| 2026-07-27 | $-0.73 | $5,842,857 | 5 / 5 |
| 2026-07-28 | $-0.73 | $5,842,857 | 5 / 5 |
| 2026-07-29 | $-0.73 | $5,842,857 | 5 / 5 |
| 2026-07-30 | $-0.78 | $6,816,670 | 4 / 6 |
| 2026-07-31 | $-0.78 | $6,816,670 | 4 / 6 |
| 2026-08-01 | $-0.78 | $6,816,670 | 4 / 6 |
| 2026-08-02 | $-0.78 | $6,816,670 | 4 / 6 |
| 2026-08-03 | $-0.78 | $6,816,670 | 4 / 6 |
| 2026-08-04 | $-0.73 | $5,842,857 | 5 / 5 |
| 2026-08-05 | $-0.78 | $6,816,670 | 4 / 6 |
| 2026-08-06 | $-0.78 | $6,816,670 | 4 / 6 |
| 2026-08-07 | $-0.73 | $5,842,857 | 5 / 5 |
| 2026-08-08 | $-0.73 | $5,842,857 | 5 / 5 |
| 2026-08-09 | $-0.78 | $6,816,670 | 4 / 6 |
| 2026-08-10 | $-0.73 | $5,842,857 | 5 / 5 |
| 2026-08-11 | $-0.73 | $5,842,857 | 5 / 5 |
| 2026-08-12 | $-0.78 | $6,816,670 | 4 / 6 |
| 2026-08-13 | $-0.73 | $5,842,857 | 5 / 5 |
| 2026-08-14 | $-0.73 | $5,842,857 | 5 / 5 |
| 2026-08-15 | $-0.73 | $5,842,857 | 5 / 5 |
| 2026-08-16 | $-0.73 | $5,842,857 | 5 / 5 |
| 2026-08-17 | $-0.73 | $5,842,857 | 5 / 5 |
| 2026-08-18 | $-0.73 | $5,842,857 | 5 / 5 |
| 2026-08-19 | $-0.73 | $5,842,857 | 5 / 5 |
| 2026-08-20 | $-0.73 | $5,204,429 | 5 / 5 |
| 2026-08-21 | $-0.73 | $5,204,429 | 5 / 5 |
| 2026-08-22 | $-0.73 | $5,204,429 | 5 / 5 |
| 2026-08-23 | $-0.73 | $5,204,429 | 5 / 5 |
| 2026-08-24 | $-0.73 | $5,204,429 | 5 / 5 |
| 2026-08-25 | $-0.73 | $5,204,429 | 5 / 5 |
| 2026-08-26 | $-0.73 | $5,204,429 | 5 / 5 |
| 2026-08-27 | $-0.73 | $5,204,429 | 5 / 5 |
| 2026-08-28 | $-0.73 | $5,204,429 | 5 / 5 |
| 2026-08-29 | $-0.73 | $5,204,429 | 5 / 5 |
| 2026-08-30 | $-0.73 | $5,204,429 | 5 / 5 |
| 2026-08-31 | $-0.73 | $5,204,429 | 5 / 5 |
| 2026-09-01 | $-0.73 | $5,204,429 | 5 / 5 |
| 2026-09-02 | $-0.73 | $5,204,429 | 5 / 5 |
| 2026-09-03 | $-0.73 | $5,204,429 | 5 / 5 |
| 2026-09-04 | $-0.73 | $5,204,429 | 5 / 5 |
| 2026-09-05 | $-0.73 | $5,204,429 | 5 / 5 |
| 2026-09-06 | $-0.73 | $5,204,429 | 5 / 5 |
| 2026-09-07 | $-0.73 | $5,204,429 | 5 / 5 |
| 2026-09-08 | $-0.73 | $5,204,429 | 5 / 5 |
| 2026-09-09 | $-0.73 | $5,204,429 | 5 / 5 |
| 2026-09-10 | $-0.73 | $5,204,429 | 5 / 5 |
| 2026-09-11 | $-0.73 | $5,204,429 | 5 / 5 |
| 2026-09-12 | $-0.73 | $5,204,429 | 5 / 5 |
| 2026-09-13 | $-0.73 | $5,204,429 | 5 / 5 |
| 2026-09-14 | $-0.73 | $5,204,429 | 5 / 5 |
| 2026-09-15 | $-0.73 | $5,204,429 | 5 / 5 |
| 2026-09-16 | $-0.73 | $5,204,429 | 5 / 5 |
| 2026-09-17 | $-0.73 | $5,204,429 | 5 / 5 |
| 2026-09-18 | $-0.73 | $5,204,429 | 5 / 5 |
| 2026-09-19 | $-0.73 | $5,204,429 | 5 / 5 |
| 2026-09-20 | $-0.73 | $5,204,429 | 5 / 5 |
| 2026-09-21 | $-0.73 | $5,204,429 | 5 / 5 |
| 2026-09-22 | $-0.73 | $5,204,429 | 5 / 5 |
| 2026-09-23 | $-0.73 | $5,204,429 | 5 / 5 |
| 2026-09-24 | $-0.73 | $6,071,833 | 5 / 5 |
| 2026-09-25 | $-0.73 | $6,071,833 | 5 / 5 |
| 2026-09-26 | $-0.73 | $6,071,833 | 5 / 5 |
| 2026-09-27 | $-0.73 | $6,071,833 | 5 / 5 |
| 2026-09-28 | $-0.73 | $6,071,833 | 5 / 5 |
| 2026-09-29 | $-0.73 | $6,071,833 | 5 / 5 |
| 2026-09-30 | $-0.73 | $6,083,333 | 5 / 5 |
| 2026-10-01 | $-0.73 | $6,083,333 | 5 / 5 |
| 2026-10-02 | $-0.73 | $6,083,333 | 5 / 5 |
| 2026-10-03 | $-0.73 | $6,083,333 | 5 / 5 |
| 2026-10-04 | $-0.73 | $6,083,333 | 5 / 5 |
| 2026-10-05 | $-0.73 | $6,083,333 | 5 / 5 |
| 2026-10-06 | $-0.75 | $5,642,857 | 5 / 5 |
| 2026-10-07 | $-0.75 | $5,642,857 | 6 / 5 |
| 2026-10-08 | $-0.75 | $5,642,857 | 6 / 6 |
| 2026-10-09 | $-0.75 | $5,642,857 | 6 / 6 |
| 2026-10-10 | $-0.75 | $5,642,857 | 6 / 6 |
| 2026-10-11 | $-0.75 | $5,642,857 | 6 / 6 |
| 2026-10-12 | $-0.75 | $5,642,857 | 6 / 6 |
| 2026-10-13 | $-0.75 | $5,642,857 | 6 / 6 |
| 2026-10-14 | $-0.75 | $5,642,857 | 6 / 6 |
| 2026-10-15 | $-0.75 | $5,642,857 | 6 / 6 |
| 2026-10-16 | $-0.75 | $5,642,857 | 6 / 6 |
| 2026-10-17 | $-0.75 | $5,642,857 | 6 / 6 |
| 2026-10-18 | $-0.78 | $5,642,857 | 7 / 6 |
| 2026-10-19 | $-0.78 | $5,642,857 | 7 / 6 |
| 2026-10-20 | $-0.78 | $5,642,857 | 7 / 6 |
| 2026-10-21 | $-0.78 | $5,642,857 | 7 / 6 |
| 2026-10-22 | $-0.78 | $5,642,857 | 7 / 6 |
| 2026-10-23 | $-0.78 | $5,642,857 | 7 / 6 |
| 2026-10-24 | $-0.78 | $5,642,857 | 7 / 6 |
| 2026-10-25 | $-0.79 | $4,937,500 | 7 / 6 |
| 2026-10-26 | $-0.79 | $4,937,500 | 7 / 7 |
| 2026-10-27 | $-0.79 | $4,937,500 | 7 / 7 |
| 2026-10-28 | $-0.80 | $4,937,500 | 7 / 7 |
| 2026-10-29 | $-0.80 | $4,937,500 | 7 / 6 |
| 2026-10-30 | $-0.80 | $4,937,500 | 7 / 6 |
| 2026-10-31 | $-0.80 | $4,937,500 | 7 / 6 |
| 2026-11-01 | $-0.80 | $4,937,500 | 7 / 6 |
| 2026-11-02 | $-0.80 | $4,937,500 | 7 / 6 |
| 2026-11-03 | $-0.80 | $4,937,500 | 7 / 6 |
| 2026-11-04 | $-0.80 | $4,937,500 | 7 / 6 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 10 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
0 raises · 0 cuts · 0 unchanged · 2 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.